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Abstract: 
 
Study objective: To examine the relationship between psychiatric comorbidity and quality of 
life in patients awaiting lung transplantation. Setting: Duke University Medical Center/Lung 
Transplantation Program. Participants: One hundred patients with end-stage pulmonary disease 
listed for lung transplantation. Measurements and results: Twenty-five percent (n = 25) of the 
sample met diagnostic criteria for at least one current mood of anxiety disorder. Controlling for 
age, gender, ethnicity, percentage of predicted FEV, and lung disease diagnosis, patients with a 
current psychiatric diagnosis reported poorer general quality of life (p < 0.0001), poorer disease-
specific quality of life (p < 0.0001), greater shortness of breath (p = 0.01), more symptoms of 
psychological distress (p < 0.0001), lower levels of social support (p < 0.0001), and fewer 
positive health habits (p < 0.04) than their counterparts without a psychiatric diagnosis. 
Conclusions: Psychiatric comorbidity affects a significant portion of patients awaiting lung 
transplantation and is associated with decreased health-related quality of life. 
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Article:  
 
Since the first successful human lung transplant operations were performed in the mid 1980s, 
cadaveric lung allotransplantation has grown into an acceptable therapy for many end-stage 
pulmonary diseases. Unfortunately, there are many more patients awaiting lung transplantation 
than there are organs available.1 Furthermore, short- and long-term outcomes for lung 
 
  Abbreviations: DSM IV = Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition; FEV1% = 
percentage of predicted FEV1; GHQ = General Health Questionnaire; INSPIRE = Investigational Study of 
Psychological Intervention in Recipients of Lung Transplant; MANCOVA = multivariate analysis of covariance 
PQLS = Pulmonary-Specific Quality of Life Seale; SF-36 = Short Form-36: SOBQ = UCSD Shortness of Breath 
Questionnaire 
transplantation lag behind those of other solid-organ transplants, with 1-year and 5-year survival 
rates of 76% and 43%, respectively, for lung transplant recipients.2 Given the scarcity of donor 
lungs and the risk associated with the transplant surgery, careful screening of potential lung 
transplant candidates is essential to ensure optimal outcomes. This screening process not only 
involves a comprehensive medical evaluation, but also includes a thorough psychological 
assessment. 
 
End-stage pulmonary disease is associated with significant psychological distress,3-5 with up to 
47% of lung transplant candidates meeting criteria for at least one psychiatric disorder.5 Previous 
studies have found that psychiatric illness and other psychosocial problems are related to poor 
posttransplant outcomes, such as more rejection episodes,6 increased length of hospitalization,7 
and higher levels of emotional distress.8,9 Although quality of life is considered an important 
measure of outcome following lung transplantation, little attention has been devoted to the 
relation between psychiatric illness and quality of life in candidates for this surgery. Because 
many patients awaiting lung transplantation will not survive long enough to receive a transplant, 
it is important to examine factors influencing quality of life before as well as after transplant. 
Therefore, the purpose of the present study was to examine the relationship of psychiatric 
comorbidity and various measures of quality of life in a relatively large series of patients 
awaiting lung transplantation. 
 
MATERIALS AND METHODS 
 
Patient Population 
 
Patients who were candidates for lung transplantation at Duke University Medical Center 
between November 2000 and January 2002 were recruited for this study. Inclusion criteria were 
as follows: age ≥18 years, current placement on the waiting list for an initial single or bilateral 
lung transplant, and the ability to complete written and telephone assessments (ie, basic English 
proficiency; lack of significant hearing, speaking, or visual difficulties; and a working telephone 
number). Participants agreed to enroll in a clinical trial of a telephone-based stress management 
intervention being conducted at Duke University and Washington University Medical Centers in 
which they would be randomly assigned to either stress management or usual care. This report 
presents baseline data from 100 patients who enrolled in this clinical trial at Duke University. 
 
A total of 236 patients were approached to participate in this study. Of these, 98 patients (42%) 
were ineligible for the following reasons: not listed for lung transplantation (n = 54), listed for 
lung retransplantation (n = 1), required multiple-organ transplants (n = 12), underwent 
transplantation before enrolling in the study (n = 17), died before enrolling in the study (n = 8), 
difficulty speaking due to damaged vocal cords of shortness of breath (n = 2), could not be 
reached by telephone (n = 3), and already participating in a competing protocol (n = 1). Of the 
remaining eligible patients, 38 patients (28%) refused to participate in the study. There were no 
significant differences with respect to age, gender, time waiting on the transplant list, or disease 
severity (measured by percentage of predicted FE1 [FE1%]) between those who declined to 
participate and those who participated. 
 
Procedure 
 
Patients were initially contacted either by mail or in person during their pulmonary clinic 
appointment. After patients provided written informed consent to participate, they were given a 
battery of psychosocial measures, which they were asked to complete and return by mail. 
Participants were then administered a psychiatric diagnostic interview over the telephone by a 
trained clinical psychologist (K.M.). Pulmonary function data were obtained from medical 
records. The consent form and all study procedures were approved by the institutional review 
board at Duke University Medical Center. 
 
Psychosocial Measures 
 
Medical Outcomes Survey, Short Form-36: The Medical Outcomes Survey, Short Form-36 (SF-
36) is a questionnaire that measures quality of life by assessing eight life domains: physical 
functioning, social functioning, role limitations due to physical problems, role limitations due to 
emotional problems, pain, mental health, vitality, and general health perception.10 The SF-36 has 
been used with patients with chronic lung disease.11,12 Higher scores indicate better health-
related quality of life. 
 
Pulmonary-Specific Quality of Life Scale: The Pulmonary-Specific Quality of Life Scale (PQLS) 
was developed for use with persons with chronic lung disease.13,14 The PQLS has seven 
subscales: physical functioning, psychological/emotional status, functional status/activities of 
daily living, social activities, intimacy/ relationships/sexuality, occupational functioning, and 
view of self. Lower scores indicate better functioning. 
 
Beck Depression Inventory II: The Beck Depression Inventory II is a 21-item self-report scale 
measuring cognitive, affective, and somatic symptoms of depression.15 A higher score indicates 
more severe depressive symptoms. 
 
Spielberger State Anxiety Inventory: The Spielberger State Anxiety Inventory consists of 20 
items assessing current anxiety level.16 This scale was originally developed to investigate anxiety 
in normal populations and has also been used in medical and surgical patients. A higher score 
indicates greater anxiety. 
 
General Health Questionnaire: The General Health Questionnaire (GHQ) is a 60-item scale 
developed to screen for nonpsychotic psychiatric disorders by assessing somatic symptoms, 
symptoms of anxiety, social dysfunction, and depressive symptoms.17 A higher score indicates 
greater psychological distress. 
 
Perceived Stress Scale: The Perceived Stress Seale is a 14-item scale that measures perceived 
stress, which is the extent to which life events are viewed as unpredictable and uncontrollable.18 
A higher score indicates greater stress. 
 
Life Orientation Test-Revised: The Life Orientation Test-Revised is a 10-item scale assessing 
generalized optimism, broadly defined as the expectation that positive events will occur.19 A 
higher score indicates greater optimism. 
 
Perceived Social Support Scale: The Perceived Social Support Scale consists of 12 items 
assessing perceived social support from family, friends, and significant other.20,21 A higher score 
indicates greater overall perceived support. 
 
UCSD Shortness of Breath Questionnaire: The UCSD Shortness of Breath Questionnaire 
(SOBQ) is a 24-item scale assessing the degree of shortness of breath experienced while 
performing various daily activities.22 A higher score indicates greater overall shortness of breath. 
 
Health Practices Index: The Health Practices Index is a 15-item survey assessing a variety of 
health indicators, including body mass index, cigarette smoking, alcohol use, sleep habits, and 
physical activity level.23 A higher store indicates a greater number of positive health habits. 
 
Psychiatric Diagnosis 
 
A modified version of the Structured Clinical Interview for Diagnostic and Statistical Manual 
for Mental Disorders, Fourth Edition (DSM-IV), Axis I Disorders Nonpatient Edition24 was 
administered to participants by telephone in order to determine the presence of current and past 
psychiatric diagnoses. Modules A (mood episodes), B/C (psychotic symptom screen), and I 
(adjustment disorder) were included in their entirety. Also included were the portions of module 
F (anxiety disorders) assessing panic disorder, social phobia, generalized anxiety disorder, 
anxiety disorder due to a general medical condition, substance-induced anxiety disorder, and 
anxiety disorder not otherwise specified. Finally, the section of module J (optional disorders) 
assessing minor depression also was included. It should be noted that minor depression is not a 
DSM-IV diagnosis, but is instead considered a research diagnosis for further study. However, 
patients with minor depression do meet criteria for the DSM-IV diagnosis of depression not 
otherwise specified. The Axis I Disorders Nonpatient Edition was administered and scored by a 
clinical psychologist unaware of responses to the quality-of-life test battery and medical 
measures. 
 
Pulmonary Function 
 
FE1% was obtained for all but one of the participants. Because patients usually underwent 
spirometry testing as a routine part of their pulmonary clinic visits, medical charts were reviewed 
to obtain FE1% values closest to the date of the psychosocial assessments. The average interval 
between FE1% testing and the quality-of-life measures was 56 days (SD, 98 days; range, 0 to 724 
days). 
 
Statistical Analysis 
 
To determine whether patients with a current psychiatric diagnosis differed from patients without 
a current diagnosis with respect to demographic variables, χ2 tests and independent two-tailed t 
tests were conducted. To determine whether patients with a current psychiatric diagnosis differed 
from patients without a current diagnosis with respect to psychosocial measures, multivariate 
analysis of covariance (MANCOVA) and analysis of covariance models were used. Two 
MANCOVA models were performed with the subscales of the SF-36 and the subscales of the 
PQLS as the dependent variables, respectively. Analysis of covariance models were performed 
for all other psychosocial measures and for each of the individual subscales of the SF-36 and 
PQLS. All models included absence/presence of a current psychiatric diagnosis as a between-
subjects factor and age, gender, ethnicity, FE1%, and lung disease diagnosis as covariates. FE1% 
was unavailable for one patient, so we imputed this value by substituting the median FE1% of the 
other nine patients in our sample with the same lung disease diagnosis, primary pulmonary 
hypertension. All statistical analyses were performed using SAS 8.2 software (SAS Institute; 
Cary, NC). 
 
RESULTS 
 
Sample Demographic Characteristics 
 
The sample consisted of 57 women (57%) and 43 men (43%) with a mean age of 48.6 years (SD, 
11.7 years). The most common lung diseases were COPD (42%) and fibrotic lung disease (31%). 
The majority of participants were white (82%), married (67%), and had at least a high school 
education (87%). Only 12% of the sample were employed full-time. There were no significant 
differences between patients with at least one current psychiatric diagnosis and those with no 
current psychiatric diagnosis on any demographic variables (Table 1). 
 
Table 1. Demographic Characteristics of Patients Awaiting Lung Transplantation* 
Characteristics 
No Current Psychiatric 
Diagnosis  (n = 75) 
At Least One Current 
Psychiatric Diagnosis (n = 25) Entire Sample (n=100) 
Age, yr† 48.4 (12.5) 49.2 (9.1) 48.6 (11.7) 
Male gender 32 (42.7) 11 (44) 43 (43) 
White race 61 (81.3) 21 (84) 82 (82) 
≥ High school education 65 (86.7) 22 (88) 87 (87) 
Married 49 (65.3) 18 (72) 67 (67) 
Employed full-time 10 (13.3) 2 (8) 12 (12) 
6-minute walk in feet† 1,139 (418.3) [n = 71] 1,097 (370.8) [n = 24] 1,129 (405.4) [n = 95] 
FEV1%† 32.7 (19.6) 34.5 (18.7) 32.9 (19.6) 
Oxygen dependent 64 (85.3) 22 (88) 86 (86) 
Lung disease diagnosis    
COPD 33 (44) 9 (36) 42 (42) 
Cystic fibrosis 11 (14.7) 5 (20) 16 (16) 
Fibrotic disease 21 (28) 10 (40) 31 (31) 
Other 10 (13.3) 1 (4) 11 (11) 
*Data are presented as No. (%) unless otherwise indicated. 
†Mean (SD). 
 
Prevalence of Psychiatric Disorders 
 
Among our sample of patients awaiting lung transplantation, 25% (n = 25) had a diagnosis of at 
least one current mood of anxiety disorder. Of these, 28% (7 of 25 patients) had two current 
psychiatric disorders. Panic disorder and anxiety disorder not otherwise specified were the most 
common current diagnoses, identified in 7% and 6% of the sample, respectively. The prevalence 
of a past psychiatric disorder was 18%, with a history of major depression being the most 
common, identified in 15% of the patients. Among patients with a current psychiatric diagnosis, 
24% reported treatment with antidepressant medication, 8% reported treatment with anxiolytic 
medication, 32% reported treatment with both antidepressant and anxiolytic medications, 8% 
reported combination treatment consisting of psychotropic medication plus counseling, and 36% 
reported no current mental health treatment. Table 2 presents the prevalence of all psychiatric 
disorders identified in our sample. 
 
Table 2. Prevalence of Mood and Anxiety Disorders in Patients Awaiting Lung Transplantation* 
Disorders Current Past 
Mood   
Major depression, single episode 1 11 
Major depression, recurrent 4 4 
Dysthymic disorder 1 0 
Mood disorder due to general medical condition 1 0 
Depression NOS (minor depression) 5 0 
Anxiety   
Panic disorder 7 1 
Generalized anxiety disorder 3 0 
Social phobia 3 1 
Adjustment disorder with anxiety 1 0 
Anxiety disorder NOS 6 1 
*Data are presented as %. NOS = not otherwise specified. 
 
Table 3. Health-Related Quality of Life in Patients Awaiting Lung Transplantation* 
Quality-of-Life Measure 
No Current Psychiatric 
Diagnosis (n = 75) 
At Least One Current 
Psychiatric Diagnosis (n = 25) Entire Sample (n = 100) 
SF-36 scales    
Physical functioning 31.8 (23.7) 23.9 (22.2) 29.8 (23.5) 
Physical role limitations 36.3 (40.7) 9.0 (22.7)‡ 29.5 (38.8) 
Pain 70.2 (23.2) 56.8 (26.6)† 66.9 (24.6) 
General health 27.7 (19.7) 27.3 (15.9) 27.6 (18.7) 
Vitality 42.3 (22.3) 31.2 (19.0)† 39.5 (22.0) 
Social functioning 50.0 (18.7) 49.0 (23.9) 49.8 (20.0) 
Emotional role limitations 87.1 (26.2) 44.0 (35.6)‡ 76.3 (34.3) 
Mental health 81.8 (12.2) 61.9 (14.0)‡ 76.8 (15.3) 
PQLS scales    
Physical functioning 4.1 (1.0) 4.5 (0.7)† 4.2 (0.9) 
Psychological status 2.0 (0.7) 3.1 (0.7)‡ 2.3 (0.9) 
Activities of daily living 2.3 (0.9) 2.9 (1.2)† 2.4 (1.0) 
Social activities 3.5 (0.9) 3.8 (0.9) 3.6 (0.9) 
Relationships 3.0 (0.7) 2.9 (0.8) 3.0 (0.7) 
Occupational functioning 4.1 (1.2) 4.5 (0.9) 4.2 (1.2) 
View of self 2.7 (1.1) 3.4 (1.0)‡ 2.9 (1.1) 
Total 21.7 (4.3) 25.1 (3.5)‡ 22.6 (4.3) 
SOBQ 61.2 (22.5) 72.0 (23.3)† 63.9 (23.1) 
*Data are presented as group mean (SD). On the SF-36 higher numbers indicate better functioning, whereas on the 
PQLS and SOBQ lower numbers indicate better functioning. 
†p < 0.05, patients with vs patients without current psychiatric diagnosis. 
‡ p < 0.01, patients with vs patients without current psychiatric diagnosis. 
 
Health-Related Quality of Life 
 
SF-36: A MANCOVA performed on the set of SF-36 subscales revealed a significant group 
effect (p < 0.0001), indicating that, controlling for age, gender, ethnicity, FEV1%, and lung 
disease diagnosis, there were differences in quality of life between patients with at least one 
current psychiatric diagnosis and those without a diagnosis. Examination of univariate analyses 
indicated that compared to patients without a comorbid psychiatric diagnosis, patients with a 
psychiatric diagnosis had greater physical role limitations (p = 0.002), physical pain (p = 0.01), 
and emotional role limitations (p < 0.0001), along with less vitality (p = 0.02), poorer mental 
health (p < 0.0001) and a tendency toward poorer physical functioning (p = 0.09) [Table 3]. 
 
PQLS: There was a significant multivariate group effect for the set of PQLS subscales (p < 
0.0001). Results of univariate analyses revealed that as compared to patients who did not have a 
current psychiatric diagnoses, patients with a psychiatric diagnosis reported poorer physical 
functioning (p = 0.04) and psychological status (p < 0.0001), decreased ability to perform 
activities of daily living (p = 0.01), a more negative view of the self (p = 0.007), and a tendency 
toward poorer occupational functioning (p = 0.08) [Table 3]. 
 
Shortness of Breath: Patients with a current psychiatric diagnosis reported greater shortness of 
breath (p = 0.01) than patients without a psychiatric diagnosis. 
 
Psychosocial Measures 
 
After controlling for age, gender, ethnicity, FEV1%, and lung disease, patients with at least one 
current psychiatric diagnosis were found to report greater depressive symptoms (p < 0.0001), 
greater anxiety symptoms (p < 0.0001), more psychological distress as assessed by the GHQ (p < 
0.0001), and higher levels of stress (p < 0.0001) than patients without a current psychiatric 
diagnosis. Patients with a psychiatric diagnosis also reported lower levels of optimism (p = 
0.004), fewer positive health habits (p = 0.04), and less perceived social support (p < 0.0001) 
than their counterparts without a current psychiatric diagnosis (Table 4). 
 
Table 4. Psychosocial Measures in Patients Awaiting Lung Transplantation* 
Psychosocial Measures 
No Current Psychiatric 
Diagnosis (n = 75) 
At Least One Current 
Psychiatric Diagnosis 
(n = 25) 
Entire Sample 
(n = 100) 
Beck Depression Inventory II 8.5 (6.0) 15.6 (5.5)‡ 10.3 (6.6) 
Anxiety (Spielberger State Anxiety Inventory) 33.4 (9.9) 42.8 (8.7)‡ 35.8 (10.4) 
Psychological distress (GHQ) 41.9 (18.0) 63.3 (20.3)‡ 47.3 (20.7) 
Perceived stress 17.2 (7.2) 26.7 (5.9)‡ 19.6 (8.0) 
Optimism (Life Orientation Test-Revised) 16.9 (3.9) 14.4 (4.1)‡ 16.2 (4.1) 
Social support 77.0 (7.3) 67.7 (11.0)‡ 74.7 (9.2) 
Health Practices Index 3.2 (0.9) 2.9 (1.1)† 3.1 (1.0) 
*Data are presented as group mean (SD). 
†p < 0.05, patients with vs patients without current psychiatric diagnosis. 
‡ p < 0.01, patients with vs patients without current psychiatric diagnosis. 
 
DISCUSSION 
 
In the present study, one fourth of patients with end-stage pulmonary disease awaiting lung 
transplantation met diagnostic criteria for a current mood or anxiety disorder. Psychiatric 
comorbidity in these patients was associated with significantly decreased quality of life across a 
number of domains. Specifically, lung transplant candidates with a psychiatric diagnosis reported 
poorer physical functioning, more shortness of breath, fewer positive health habits, less social 
support, more stress, and more symptoms of depression and anxiety than their counterparts with 
no current psychiatric disorder. Because persons with chronic lung disease exhibit decreased 
quality of life in comparison to healthy persons,25 our results indicate an additional burden of 
impaired quality of life associated with comorbid psychiatric disorder. This effect on quality of 
life occurred independent of age, gender, ethnicity, and even severity and type of lung disease. 
One implication of these findings is that identifying and treating psychiatric disorder in patients 
awaiting lung transplantation may improve their overall quality of life. In our study, 36% of the 
patients with a current psychiatric diagnosis were receiving no treatment, suggesting that mental 
disorders are generally underidentified and undertreated in this population. Indeed, inadequate 
mental health treatment may partially explain our finding of poorer quality of life in patients with 
current psychiatric disorders. Unfortunately, we were unable to compare quality of life between 
patients with treated psychiatric disorder and patients with untreated psychiatric disorder because 
of limited statistical power due to small sample size. Additional studies are needed to determine 
the optimal treatment of psychiatric disorders in these medically ill patients and to determine the 
degree of impact mental health treatment might have on quality of life. 
 
Our finding that mood and anxiety disorder, particularly panic disorder, is common among 
patients with end-stage lung disease is consistent with previous studies.3-5 Because patients with 
major nonpulmonary medical conditions and severe psychosocial dysfunction are excluded from 
listing for lung transplantation, our rate of 25% psychiatric comorbidity is likely to underestimate 
the true rate of psychiatric disturbance in a broader sample of end-stage pulmonary patients. Our 
results suggest that even when patients undergo extensive screening and self-selection for lung 
transplantation, psychiatric comorbidity is significant. The occurrence of frequent episodes of 
dyspnea and hyperventilation, symptoms of lung disease as well as triggers of anxiety, may 
explain why individuals with pulmonary disease are particularly susceptible to panic and 
anxiety.26 However, another possible explanation for findings of a high rate of anxiety disorders 
in patients with pulmonary diseases is an increased false-positive rate for the diagnosis of panic 
and anxiety disorders due to symptom overlap with lung disease. 
 
Patients with end-stage pulmonary disease who also are awaiting lung transplantation experience 
unique stressors, including separation from their support system due to relocation, a progressing 
course of illness, and fear of not receiving donor lungs in time,27 that make the waiting period a 
time of especially high risk for psychological distress. For example, Craven3 found that 21% of 
patients acquired psychiatric symptoms while on the waiting list for lung transplant, highlighting 
the importance of continuing mental health follow-up of these patients after the initial evaluation. 
Similarly, in our previous work, we have shown that patients awaiting lung transplant tend to 
show declines in social support and other indexes of quality of life with increasing time on the 
waiting list.14 However, in the same study, improvement in quality of life, including better 
physical functioning, was reported in patients who received a psychosocial intervention, despite 
the fact that these patients did not necessarily have any psychiatric diagnosis. Therefore, we 
might expect even greater improvement in quality of life upon treatment of psychiatric disorder 
in lung transplant candidates. However, it should be noted that even in the current sample, 
greater psychological distress (as measured by the GHQ) was associated with decreased 
pulmonary-specific quality of life and greater shortness of breath independent of the presence of 
a current psychiatric diagnosis (data not shown). This suggests that psychosocial interventions 
should be considered even for those pulmonary patients who do not meet criteria for a 
psychiatric diagnosis. 
 
Psychiatric disorder in patients awaiting transplant may be linked to adverse health outcomes as 
well as reduced quality of life. For example, one study28 identified quality of well-being, a 
measure of physical and social functioning, as the strongest predictor of survival in lung 
transplant candidates. Notably, we found that patients with a comorbid psychiatric condition 
reported more dyspnea, which has been shown to be a better predictor of survival than FEV1 in 
patients with chronic lung disease.29 Our study also demonstrated that patients with a current 
mood or anxiety disorder practiced fewer health-promoting habits, suggesting that psychological 
disturbance could lead to poorer health outcomes by influencing compliance, especially in light 
of other studies6,30 demonstrating that psychosocial issues are related to poor medical 
compliance. 
 
There are several methodologic issues that deserve comment. First, because we only studied 
patients on the waiting list for lung transplantation, our sample may not be representative of all 
patients with end-stage lung disease, as pulmonary patients with especially severe and intractable 
psychiatric or social problems would not have been listed for transplant. Also, it should be noted 
that the association of psychiatric disorder with poor quality of life does not imply a causal 
relationship. Although it is possible that a psychiatric disorder may result in decreased quality of 
life, indexes of poor quality of life (such as marked functional impairment and high levels of 
pain) could increase the risk of psychiatric illness. It is unclear whether the patients in our study 
who met criteria for a current psychiatric disorder were more physically ill than their 
counterparts without psychiatric disturbance. The patients with psychiatric disorders did report 
greater shortness of breath and reduced physical functioning; however, their mean FEV1% was 
not statistically different from that of patients without current psychiatric disorder. A prospective 
study design would be needed to determine if more severe physical illness plays a causal role in 
poorer psychiatric and quality-of-life outcomes in patients awaiting lung transplant. Finally, 
although we suggest that the presence of psychiatric disorder may be associated with adverse 
medical outcomes and effective treatment of psychiatric disorder may be associated with 
improvements of physical health, long-term follow-up data are needed. The INSPIRE 
(Investigational Study of Psychological Intervention in Recipients of Lung Transplant) trial 
hopes to provide these data in the future. 
 
In summary, we found that the presence of current mood or anxiety disorder was related to 
significantly decreased quality of life in patients with end stage pulmonary disease awaiting lung 
transplantation. Our results suggest that identifying and treating psychiatric disorder in this 
population could result in improved psychosocial and medical outcomes for these patients. 
 
APPENDIX 
 
INSPIRE Investigators: James A. Blumenthal, PhD (Director, Behavioral Medicine); Robert M. 
Carney, PhD (Co-director, Behavioral Medicine); R. Duane Davis, MD (Surgical Director); 
Scott M. Palmer, MD (Medical Director); Michael Babyak, PhD; Robyn Claar, PhD; Iris Csik, 
MSW; Francis Keefe, PhD; Kenneth Freedland, PhD; Elizabeth Gullette, PhD; Joel Hughes, 
PhD; Kari Merrill, PhD; Melissa Napolitano, PhD; Jennifer Norten, PhD; Priti I. Parekh, PhD; 
Victor Tapson, MD; and Elbert Trulock, MD. 
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